GEN Exclusives

More »

GEN Poll

Oct 15, 2012

Biosimilars and Patient Safety

Under the Affordable Care Act, Congress authorized the FDA to create a new pathway for the approval of copies of next-generation biologic drugs that are already approved and on the market. These copies, called biosimilars, are near-reproductions of a biologic drug, and if manufactured safely they can expand access to life-saving, life-enhancing medicines. However, a small difference in manufacturing process or in the cell line can alter the molecular structure between an original product and its biosimilar copies. Even slight variations could result in serious health implications for patients. So, how would you feel about replacing your drugs with biosimilars?

If one of your prescription drugs were switched to a biosimilar, how comfortable would you be with the switch?

Completely comfortable
Mostly comfortable
Mostly uncomfortable
Give me the real thing!

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »